Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (SHSE: 600721)
Health Care · Pharmaceuticals · CN
CN¥13.25
-4.06% today · +41.6% 1Y
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (SHSE: 600721) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $757.95M and employs 672 people.
Over the last twelve months the share price has gained 41.6%, trading between 6.25 and 15.09.
Tweenvest scores Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd across four factors: quality 67/100, value 4/100, growth 12/100, dividend 12/100. Its strongest factor is quality.
600721 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $757.95M
- Revenue (TTM)
- $51.99M
- P/E
- 191.35
- EPS
- 0.07
- Dividend yield
- 0.30%
- Beta (5Y)
- -0.22
- 52-week high
- CN¥15.09
- 52-week low
- CN¥6.25
- Avg volume (3M)
- —
- Shares outstanding
- 384.55M
- Employees
- 672
- Next earnings
- —
About Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd conducts its operations across a diverse range of business sectors. Its core activities encompass pharmaceutical research and development, clinical studies, and the field of biomedicine, alongside investments in commercial properties and various other ventures. This enterprise, officially renamed Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd in July 2021, previously operated as Xinjiang Baihuacun Co., Ltd. Established in 1959, the company maintains its headquarters in Urumqi, China.
- ISIN
- CNE000000KQ1
- Founded
- 1959
- Listed since
- Jun 26, 1996
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,238.28 | -1.36% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.96 | +0.27% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $149.49 | -2.01% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.20 | -1.70% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.54 | -1.52% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.89 | -0.66% |
Figures last refreshed Aug 18, 2026.